Page last updated: 2024-11-04

temozolomide and Necrosis

temozolomide has been researched along with Necrosis in 28 studies

Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.

Research Excerpts

ExcerptRelevanceReference
"To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)."9.19Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014)
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed."7.80Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014)
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line."7.77Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011)
"Temozolomide is the major drug in the treatment of malignant gliomas."7.76Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010)
"Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide."7.75Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009)
" Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm."7.73Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006)
"Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy."6.84Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017)
"Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy."5.62Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021)
"Osthole was the most effective."5.56Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020)
"Malignant melanomas are highly resistant to chemotherapy."5.35Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009)
"Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease."5.32In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004)
"To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)."5.19Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014)
"Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma."5.12Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. ( Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A, 2007)
"The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor) and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells."4.02Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment. ( Bądziul, D; Hułas-Stasiak, M; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Pawelec, J; Pawlikowska-Pawlęga, B; Reichert, M; Rzeski, W; Sumorek-Wiadro, J; Wasiak, M; Wertel, I; Zając, A, 2021)
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed."3.80Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014)
"The aim of the present study was to investigate the kinetics of the effects exerted by Temodal and quercetin on the survival of the human astrocytoma MOGGCCM cell line."3.77Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells. ( Jakubowicz-Gil, J; Langner, E; Rzeski, W, 2011)
"Temozolomide is the major drug in the treatment of malignant gliomas."3.76Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. ( Akmansu, M; Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Oner, Y; Ozturk, B; Uncu, D; Yaman, E; Yildiz, R, 2010)
"Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide."3.75Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009)
"Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy."3.74MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008)
" Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm."3.73Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006)
"Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy."2.84Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017)
"Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity."2.61Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019)
"Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone."2.44Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008)
"Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy."1.62Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021)
"Differentiating treatment necrosis from tumor recurrence poses a diagnostic conundrum for many clinicians in neuro-oncology."1.62Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas. ( Cui, Y; Gao, F; Jiang, H; Li, M; Lin, S; Ren, X; Zhao, W, 2021)
"Osthole was the most effective."1.56Coumarins modulate the anti-glioma properties of temozolomide. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Wertel, I; Zając, A, 2020)
"Glioblastoma is the most common and aggressive glioma, characterized by brain invasion capability."1.48Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets. ( Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N, 2018)
"Lycopene is a fat soluble red-orange carotenoid pigment present in tomato that reduces the risk for prostate cancer, a common malignancy among men."1.39Lycopene modulates growth and survival associated genes in prostate cancer. ( Bright, JJ; Kanakasabai, S; Rafi, MM; Reyes, MD, 2013)
"Angiocentric glioma is a recently recognized benign brain tumor with unknown histogenesis."1.39Malignant glioma with angiocentric features. ( Lu, JQ; Mehta, V; Patel, S; Pugh, J; Wilson, BA, 2013)
"Malignant melanomas are highly resistant to chemotherapy."1.35Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. ( Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW, 2009)
"Malignant melanoma is considered to be a chemotherapy-refractory tumour, and the commonly used anticancer drugs do not seem to modify the prognosis of metastatic disease."1.32In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. ( Cannavò, E; D'Atri, S; Falchetti, R; Fuggetta, MP; Lanzilli, G; Ravagnan, G; Tricarico, M; Zambruno, G, 2004)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (25.00)29.6817
2010's15 (53.57)24.3611
2020's6 (21.43)2.80

Authors

AuthorsStudies
Marinho, MAG1
da Silva Marques, M1
Lettnin, AP1
de Souza Votto, AP1
de Moraes Vaz Batista Filgueira, D1
Horn, AP1
Sumorek-Wiadro, J2
Zając, A2
Bądziul, D2
Langner, E3
Skalicka-Woźniak, K1
Maciejczyk, A2
Wertel, I2
Rzeski, W3
Jakubowicz-Gil, J3
Guo, L1
Li, X1
Chen, Y1
Liu, R1
Ren, C1
Du, S1
Park, YW1
Choi, D1
Park, JE1
Ahn, SS1
Kim, H1
Chang, JH1
Kim, SH1
Kim, HS1
Lee, SK1
Gao, F1
Zhao, W1
Li, M1
Ren, X1
Jiang, H1
Cui, Y1
Lin, S1
Pawlikowska-Pawlęga, B1
Pawelec, J1
Wasiak, M1
Hułas-Stasiak, M1
Reichert, M1
Yu, A1
Faiq, N1
Green, S1
Lai, A1
Green, R1
Hu, J1
Cloughesy, TF1
Mellinghoff, I1
Nghiemphu, PL1
Costa Nunes, F1
Silva, LB1
Winter, E1
Silva, AH1
de Melo, LJ1
Rode, M1
Martins, MAP1
Zanatta, N1
Feitosa, SC1
Bonacorso, HG1
Creczynski-Pasa, TB1
Winter, SF1
Loebel, F1
Loeffler, J1
Batchelor, TT1
Martinez-Lage, M1
Vajkoczy, P1
Dietrich, J1
Jablonska, PA1
Diez-Valle, R1
Pérez-Larraya, JG1
Moreno-Jiménez, M1
Idoate, MÁ1
Arbea, L1
Tejada, S1
Garcia de Eulate, MR1
Ramos, L1
Arbizu, J1
Domínguez, P1
Aristu, JJ1
Rafi, MM1
Kanakasabai, S1
Reyes, MD1
Bright, JJ1
Iuchi, T1
Hatano, K1
Kodama, T1
Sakaida, T1
Yokoi, S1
Kawasaki, K1
Hasegawa, Y1
Hara, R1
Karpel-Massler, G1
Westhoff, MA1
Kast, RE1
Dwucet, A1
Nonnenmacher, L1
Wirtz, CR1
Debatin, KM1
Halatsch, ME1
Rubner, Y1
Muth, C1
Strnad, A1
Derer, A1
Sieber, R1
Buslei, R1
Frey, B1
Fietkau, R1
Gaipl, US1
Peca, C1
Pacelli, R1
Elefante, A1
Del Basso De Caro, ML1
Vergara, P1
Mariniello, G1
Giamundo, A1
Maiuri, F1
Naumann, SC1
Roos, WP2
Jöst, E1
Belohlavek, C1
Lennerz, V1
Schmidt, CW1
Christmann, M1
Kaina, B2
Yaman, E1
Buyukberber, S1
Benekli, M1
Oner, Y1
Coskun, U1
Akmansu, M1
Ozturk, B1
Kaya, AO1
Uncu, D1
Yildiz, R1
Eich, M1
Dianov, GL1
Digweed, M1
Rusthoven, KE1
Olsen, C1
Franklin, W1
Kleinschmidt-DeMasters, BK1
Kavanagh, BD1
Gaspar, LE1
Lillehei, K1
Waziri, A1
Damek, DM1
Chen, C1
Matuschek, C1
Bölke, E1
Nawatny, J1
Hoffmann, TK1
Peiper, M1
Orth, K1
Gerber, PA1
Rusnak, E1
Lammering, G1
Budach, W1
Raghavan, D1
Boxerman, J1
Jeyapalan, S1
Rogg, J1
Lu, JQ1
Patel, S1
Wilson, BA1
Pugh, J1
Mehta, V1
Fuggetta, MP1
D'Atri, S1
Lanzilli, G1
Tricarico, M1
Cannavò, E1
Zambruno, G1
Falchetti, R1
Ravagnan, G1
Stamatakos, GS1
Antipas, VP1
Uzunoglu, NK1
Chamberlain, MC1
Glantz, MJ1
Chalmers, L1
Van Horn, A1
Sloan, AE1
Brandes, AA1
Franceschi, E1
Tosoni, A1
Blatt, V1
Pession, A1
Tallini, G1
Bertorelle, R1
Bartolini, S1
Calbucci, F1
Andreoli, A1
Frezza, G1
Leonardi, M1
Spagnolli, F1
Ermani, M1
Brandsma, D1
Stalpers, L1
Taal, W1
Sminia, P1
van den Bent, MJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577]Phase 250 participants (Actual)Interventional2012-12-07Active, not recruiting
Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520]140 participants (Anticipated)Interventional2017-03-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for temozolomide and Necrosis

ArticleYear
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2021, Volume: 25, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob

2021
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
    Neuro-oncology, 2019, 09-06, Volume: 21, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia

2019
Bevacizumab as a treatment option for radiation-induced cerebral necrosis.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2011
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
    The Lancet. Oncology, 2008, Volume: 9, Issue:5

    Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother

2008

Trials

4 trials available for temozolomide and Necrosis

ArticleYear
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
    Journal of neuro-oncology, 2017, Volume: 134, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra

2017
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc

2019
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    International journal of radiation oncology, biology, physics, 2014, Mar-15, Volume: 88, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D

2014
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
    Journal of neuro-oncology, 2007, Volume: 82, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo

2007

Other Studies

20 other studies available for temozolomide and Necrosis

ArticleYear
Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?
    Cellular and molecular neurobiology, 2021, Volume: 41, Issue:1

    Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell

2021
Coumarins modulate the anti-glioma properties of temozolomide.
    European journal of pharmacology, 2020, Aug-15, Volume: 881

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Brain Neoplasms; Cas

2020
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
    Scientific reports, 2021, 02-03, Volume: 11, Issue:1

    Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob

2021
Role of circulating tumor cell detection in differentiating tumor recurrence from treatment necrosis of brain gliomas.
    Bioscience trends, 2021, May-11, Volume: 15, Issue:2

    Topics: Adult; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Diagnosis, Differential; Female; Glioma;

2021
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
    International journal of molecular sciences, 2021, May-13, Volume: 22, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromones; Drug

2021
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
    Biochimica et biophysica acta. General subjects, 2018, Volume: 1862, Issue:7

    Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Ge

2018
Lycopene modulates growth and survival associated genes in prostate cancer.
    The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carotenoids; Cell Cycle; Cell Line, Tumor; Cell

2013
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
    Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Ce

2014
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
    Radiation oncology (London, England), 2014, Mar-30, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba

2014
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
    Clinical neurology and neurosurgery, 2009, Volume: 111, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con

2009
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Typ

2009
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide.
    Clinical neurology and neurosurgery, 2010, Volume: 112, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz

2010
Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
    Molecular pharmacology, 2010, Volume: 78, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 7; Cell Cycle Proteins; Cell Line, Transformed

2010
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
    International journal of radiation oncology, biology, physics, 2011, Sep-01, Volume: 81, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado;

2011
Kinetic studies of the effects of Temodal and quercetin on astrocytoma cells.
    Pharmacological reports : PR, 2011, Volume: 63, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor

2011
Radiation necrosis of a high-grade glioma.
    Medicine and health, Rhode Island, 2012, Volume: 95, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine;

2012
Malignant glioma with angiocentric features.
    Journal of neurosurgery. Pediatrics, 2013, Volume: 11, Issue:3

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi

2013
In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide.
    Melanoma research, 2004, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru

2004
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
    Computers in biology and medicine, 2006, Volume: 36, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G

2006
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv

2008